Trial Profile
A Phase IIa Study to Evaluate the Safety, Tolerability and Acceptability of Long Acting Injections of the HIV Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Jul 2023
Price :
$35
*
At a glance
- Drugs Cabotegravir (Primary)
- Indications HIV infections
- Focus Adverse reactions
- Acronyms ECLAIR
- Sponsors ViiV Healthcare
- 16 Nov 2018 Results published in the HIV Clinical Trials
- 11 Apr 2016 Status changed from active, no longer recruiting to completed.
- 25 Feb 2016 Results presented at the 23rd Conference on Retroviruses and Opportunistic Infections